Skip to main content

pHBT-KRAS174
(Plasmid #248050)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 248050 Standard format: Plasmid sent in bacteria as agar stab 1 $89

Backbone

  • Vector backbone
    pET24a
  • Backbone manufacturer
    Novagen
  • Backbone size w/o insert (bp) 5233
  • Total vector size (bp) 5858
  • Vector type
    Bacterial Expression

Growth in Bacteria

  • Bacterial Resistance(s)
    Kanamycin, 30 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Growth instructions
    Depositing lab recommends using E. coli strain BL21(DE3) as a host for protein expression.
  • Copy number
    Low Copy

Gene/Insert

  • Gene/Insert name
    KRAS
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    625
  • Mutation
    includes aa 1-174 only
  • Entrez Gene
    KRAS (a.k.a. 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras, K-Ras 2, KI-RAS, KRAS1, KRAS2, NS, NS3, OES, RALD, RASK2, c-Ki-ras, c-Ki-ras2)
  • Promoter T7
  • Tag / Fusion Protein
    • His6 tag-Avi tag-TEV cleavage site (N terminal on insert)

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site NdeI (not destroyed)
  • 3′ cloning site XhoI (not destroyed)
  • 5′ sequencing primer T7 promoter
  • 3′ sequencing primer T7 terminator
  • (Common Sequencing Primers)

Resource Information

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pHBT-KRAS174 was a gift from Shohei Koide (Addgene plasmid # 248050 ; http://n2t.net/addgene:248050 ; RRID:Addgene_248050)
  • For your References section:

    Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket. Wallon L, Khan I, Teng KW, Koide A, Zuberi M, Li J, Ketavarapu G, Traaseth NJ, O'Bryan JP, Koide S. Proc Natl Acad Sci U S A. 2022 Oct 25;119(43):e2204481119. doi: 10.1073/pnas.2204481119. Epub 2022 Oct 17. 10.1073/pnas.2204481119 PubMed 36252024